



Supplemental Figure 2: Combination treatment with lomustine does not lead to an added benefit. Relative cell viability of IDH-mutant glioma lines treated with DMSO, abemaciclib 0.1 μ M, lomustine (CCNU) 25 μ M or combination of abemaciclib plus CCNU for 5 days. $n = 6$ for each treatment, mean values \pm SEM. Comparisons were made using one-way ANOVA adjusted for multiple comparisons. ns, non-significant. **, $p < 0.01$. ***, $p < 0.001$. ****, $p < 0.0001$.